TO THE EDITOR: I appreciated the article by Tosteson and colleagues (1) estimating the cost-effectiveness of back surgery. As a retired general internist who treated many patients with back pain at the White River Junction Veterans Affairs Hospital over many years in both short-term and long-term settings ("walk-in" clinic, emergency department, scheduled general medical clinic) and who has some familiarity with Richard Deyo's seminal work on back pain, several questions come to mind.
First, the authors mention that most patients were symptomatic for at least 6 to 7 months before study in multidisciplinary spine practices. Did each study site allow direct scheduled appointments, unscheduled walk-in evaluations, or emergency department evaluations (that is, direct access) to spine clinics? In other words, did each spine clinic only accept referrals from primary care physicians or emergency department professionals before spine clinic evaluation, and what was the mean time from initial symptom onset to initial spine clinic evaluation and treatment entry (disease duration)? The reason for this interest is to determine whether "referral status" or "spine clinic status" is the better measure of surgical efficacy at 2 years, and to determine whether an increased "delay to surgery" is a predictor of surgical efficacy by allowing operation to only those patients with the most durably symptomatic pain? Is there a duration of pain that might represent an inflection point in the surgical efficacy versus time-to-treatment curve?
Second, the authors' thoroughness in detailing medical costs is impressive. However, the largest single-ticket item, and the only truly "discriminating" cost among the 4 treatment groups in Table 2 , is "Surgery." As a general internist, I would be particularly interested in a breakdown of "surgical cost" into "hospital charges: Medicare reimbursable," "hospital charges: negotiated reduction," "hospital charges: patient copay," "hospital charges: patient balance billed," and "physician charges." In other words, how well do Medicare payment schedules (Part A plus Part B) reflect private insurer costs plus patient costs (total costs) and surgical cost-effectiveness? Is surgical cost-effectiveness in younger, Medicare-ineligible patients better, worse, or similar? effectiveness acceptability curve, which graphed the proportion of times the cost per quality-adjusted life-year gained achieved willingness-to-pay thresholds ranging from $20 000 to $300 000. Such graphical presentations should be helpful to those who are skeptical about the use of any particular cost-effectiveness benchmark. This methodology was also useful for demonstrating the marked impact that higher surgery costs have on the value of surgeryan issue raised by Dr. Balestra's comment. Our costing approach used national standardized Medicare payment amounts as a proxy for actual resource use. Thus, the surgery costs in our analysis were lower than what many private insurers pay. When the cost of surgery was based on 70% of the amount hospitals billed to Medicare (a higher amount that what Medicare actually pays), the cost per quality-adjusted life-year gained for surgery fell below $100 000 in only a small minority of samples.
The role that our costing approach had on comparisons between instrumented and noninstrumented fusion surgery warrants comment. Our report of no difference in cost between fusion types is largely an artifact of our costing approach, because Medicare payment amounts are minimally different for these surgical alternatives. Although no statistically significant differences in health outcome were observed between fusion types over 2 years, further follow-up of SPORT (Spine Patient Outcomes Research Trial) participants by using several approaches to costing will be important for understanding the long-term value of surgery.
Although the SPORT protocol specified a minimum symptom duration of 12 weeks, we are aware of no referral restrictions at participating centers. Previous treatments received by SPORT observational cohort participants have been described (4) and may be indicative of varied referral pathways. Our study was not designed to address the optimal symptom duration before surgery.
Health Effects and Further Consequences of the Train From Golmud to Lhasa
TO THE EDITOR: I read with great interest the article by West (1) about the train from Golmud, China, to Lhasa, Tibet; its pathophysiologic aspects; and the approaches taken to address them. However, a few more points should be made.
First, it is important to consider the possible effects of highaltitude travel on travelers who have different kinds of comorbid conditions (for example, diseases of the heart and lung) (2) and the effects of long, high-altitude, and sedentary travel on the blood coagulation profile and other conditions, such as deep venous thrombosis, the antiphospholipid syndrome (3), sickle cell disease, and protein C and protein S deficiency.
Second, some persons in developing countries, such as Tibet, are infected with tuberculosis, which could be dangerous and infective to other fellow travelers (4) because of the crowded and closed setting of the cabin (necessary to maintain oxygen concentration).
Third, the train starts at Golmud (2808 m), reaches a maximum altitude of 5074 m, and travels at an average altitude of 4500 m (Ͼ14 h over 1142 km), finally coming to Lhasa (3658 m). However, trekkers are usually advised to climb high and sleep low above an altitude of 3000 m and do acclimatization hiking, which travel on the high-altitude train does not permit.
Finally, I respect West's opinion on the political aspect regarding Tibet, the effect of the train, and present scenario of globalization (5) . But the article should have mentioned the migration of lowland people (especially Han Chinese) to Tibet (high altitude) and the effect of long-term exposure to chronic hypobaric hypoxia, which are further effects of the railway.
Matiram Pun, MBBS Tribhuyan University Teaching Hospital Kathmandu, Nepal
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healthy older adults (men and women) 60 to 81 years of age after daily administration of oral ghrelin (a secretagogue product) for 1 year. Oral administration of MK-677 increased pulsatile growth hormone secretion and serum insulin-like growth factor (IGF)-I (also known as somatomedin C) levels (2). In part, I agree with Nass and colleagues' findings, because through blood flow, the growth hormone secretagogues (comprising amino acids, some peptides, vitamins, and minerals) may reach the producing hypothalamic nuclei of growth hormone-releasing hormone (3) and, therefore, increase growth hormone secretion from the adenohypophysis. However, these treatments may not work in older persons because of atherosclerotic plaques located at the mouths of the collateral branches originating from the supraclinoid carotids and circle of Willis (3, 4) . In contrast, revascularization of the arcuate nucleus and surrounding nuclei by means of omental tissue can provoke rejuvenation (3) because the hypothalamus receives an increase in blood flow, oxygen, neurotransmitters, neurotrophic factors, cytokines, and omental stem cells through the omentum (3, 5) . For these reasons, I postulate that aging is not a normal biological process but a disease.
Hernando Rafael, MD Universidad Nacional Autónoma de México 03300 Mexico City, Mexico
TO THE EDITOR:
I read with interest the study by Nass and colleagues (1). I would like to address some critical issues, with particular reference to adverse events.
First, growing evidence suggests that IGF-I is a cytokine involved in promotion and induction of oncogenesis in different types of tumors, such as Ewing sarcoma (2), renal cell carcinoma (3), and adenocarcinoma of the gastrointestinal tract (for example, colorectal carcinoma [4] and cholangiocellular carcinoma). Why didn't the authors report the results of screening methods (fecal occult blood test, abdominal ultrasonography, colonoscopy) or staging of reported adverse events?
Second, magnetic resonance imaging and biopsy of skeletal muscle in relation to the observed effects would have been of interest in context with a clinical trial designed to prove a concept. Finally, the study did not seem to focus on adverse events or economic issues, which was part of the stated objective. I wish the authors had included a detailed discussion of the observed adverse events. Nonpharmacologic treatment strategies for decreased muscle strength and increased abdominal and intra-abdominal fat must be mentioned when discussing sarcopenia and increased blood glucose levels in elderly persons.
Markus Gaugg, MD
Kaiser Franz Josef Hospital 1100 Vienna, Austria Potential Financial Conflicts of Interest: None disclosed.
TO THE EDITOR:
The study by Nass and colleagues (1) elegantly reinforces the prevalent health strategy first proposed by Juan Ponce de Leon in 1513 (2): Simply find the magic fountain, or the right pill, and perpetual youth and perhaps even immortality will be yours, without breaking a sweat, and oh, don't worry about the cost. A contrasting approach would cite the impressive data confirming the benefits of lifestyle changes, especially exercise, in preventing and reversing frailty (3), which as a bonus reduces obesity, prevents falls, and may even improve mental status. All this without decreasing insulin sensitivity or other potential long-term side effects, such as diabetes.
Perhaps future studies testing ghrelin mimetic should include a "control group" of participants performing an aerobic and weightresistance exercise program combined with a diet intervention. One might reasonably predict that this latter group would outperform the pharmacologically enhanced cohort by a wide margin. The control group would also feel better and have lower costs while expending only sweat equity.
Jim Webster, MD, MS Northwestern University, Feinberg School of Medicine Chicago, IL 60611
IN RESPONSE:
We appreciate the thoughtful comments in response to our article and offer some clarifications.
We believe that aging is not a disease but a complex multisystem decline that occurs over decades. It is likely that MK-677 acts at multiple sites, including the hypothalamus, the pituitary, and the periphery. We have no evidence that atherosclerosis impairs its action.
We did not perform other cancer screening in these healthy older adults. Women were carefully monitored with Papanicolaou smears and mammography, and prostate-specific antigen was monitored in men. Adverse effects were reported in the Results section. A study of this size cannot assess cancer risk; however, as of 20 July 2007, more than 600 adults had been exposed to MK-677 for 6 to 12 months. The combined incidence rate for malignant conditions in any MK-677 treatment group was similar to the incidence rate in the placebo groups in these studies (Papanicolaou DA. Personal communication.). The cancer risk of growth hormone and IGF-I administration is controversial and has been extensively reviewed (1) .
As Dr. Webster points out, the benefits of exercise are well established and should always be recommended. However, physiologic studies show that the effects of resistance training on intramuscular metabolic changes achieved in elderly persons, as well as muscle growth response, are significantly less than those in younger study samples (2, 3) . Additional data suggest that in men older than 80 years of age, the capacity to gain strength with resistance training is decreased because of limited myocellular adaptive response (4) .
Furthermore, some elderly adults cannot exercise because of substantial muscle loss and frailty. Interventions that prevent or delay a decline in muscle mass would be desirable, given the expected demographic shift in the aging population. Our observations support a role for ghrelin mimetics to enhance growth hormone secretion; this resulted in both arrest of muscle mass loss as well as an increase in muscle mass. The increase in appetite also may be important. Recent data from the Health ABC (Dynamics of Health, Aging and Body Composition) Study demonstrate a significant association between change in lean mass in elderly persons and dietary protein intake (5).
Long-term studies comparing the effects of exercise with a ghrelin mimetic alone or in combination with exercise are certainly needed in elderly patients who are physically able to exercise. We emphasized that ours was a "proof-of-concept" study, and now definitive studies need to be designed and performed. 
CLINICAL OBSERVATIONS

Hepatitis B Virus Reactivation in a Patient With Resolved Hepatitis B Virus Infection Receiving Maintenance Rituximab for Malignant B-Cell Lymphoma
Background: The risk for hepatitis B virus (HBV) reactivation in patients with seemingly resolved infection who are undergoing treatment for cancer remains controversial.
Objective: To report a case of HBV reactivation in a patient with seemingly resolved infection who was undergoing lymphoma treatment.
Case Report: A 71-year-old man with mantle cell lymphoma had previously resolved hepatitis B virus (HBV) infection, defined as negative HBV surface antigen (HBsAg) with detectable antibody to HBV core antigen (anti-HBc). He had no detectable antibody to HBsAg (anti-HBsAg). Full staging investigations showed multiple enlarged lymph nodes. An excision biopsy of the right axillary lymph node was performed, and immunohistochemistry highlighted a nodular lymphoid infiltrate of CD20 ϩ B cells with strong nuclear cyclin D1 expression.
The patient was treated with 6 cycles of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP) chemotherapy without prophylactic lamivudine during or after chemotherapy. Three months after chemotherapy, he began receiving maintenance rituximab at a dose of 375 mg/m 2 once every 3 months (1). Liver enzyme levels before each cycle of maintenance rituximab were normal (Table) . One month after the third dose of maintenance rituximab, he reported increasing lethargy. His bilirubin and serum aminotransferase levels were elevated (Table) . On repeated testing, he had detectable levels of serum HBsAg, anti-HBc IgM, hepatitis B e antigen, and HBV DNA (HBV DNA level, 2.3 ϫ 10 6 copies/mL or 8.1 pg/mL).
Discussion: This case demonstrates seeming reactivation of HBV infection in a patient undergoing treatment for lymphoma, including rituximab therapy. We cannot exclude the possibility that the patient became reinfected with HBV, but we believe that reactivation of latent infection is more likely.
The risk for HBV reactivation in patients with resolved HBV who are receiving chemoimmunotherapy remains controversial. Yeo and colleagues (2) reported the risk to be as high as 24%, suggesting that prophylactic lamivudine may be indicated, but 2 larger studies (3, 4) found the risk for reactivation to be less than 2%. In all 3 studies, the prevalence of resolved HBV was relatively high (30% to 40%).
Absence of anti-HBsAg is a proposed risk factor for reactivation (2) in patients with lymphoma and resolved HBV infection who are undergoing chemoimmunotherapy. Indeed, our patient had undetectable levels of anti-HBsAg at diagnosis. However, we recently identified an anti-HBsAg-positive patient with resolved HBV infection in our institution who had reactivation 10 months after completing R-CHOP chemotherapy; therefore, we believe that presence of anti-HBsAg may not confer protection against reactivation.
Another important observation is that our patient had HBV reactivation while receiving maintenance rituximab, which is typically given for 2 years after chemotherapy. No data are available on the risk for HBV reactivation in patients with resolved HBV infection who are undergoing maintenance rituximab therapy. One study showed that rituximab, a chimeric anti-CD20 monoclonal antibody used in B-cell lymphomas, suppresses B lymphocytes, impairs their function, and may be associated with HBV reactivation (5) . Prolonged use of rituximab would make antiviral prophylaxis challenging because it is clearly not feasible to continue antiviral prophylaxis indefinitely. Furthermore, withdrawal of lamivudine after long-term prophylaxis could precipitate reactivation. Because maintenance rituximab is increasingly incorporated into the management of patients with lymphoma, the question of risk for reactivation and the role of antiviral prophylaxis will grow in importance.
Conclusion: Seemingly resolved HBV infection may reactivate in patients undergoing chemotherapy or rituximab treatment. Further studies are required to define the role of prophylaxis in this population.
enhancing mass in the right basal nuclei (Figure, A) . We began treatment with intravenous trimethoprim-sulfamethoxazole, 5 mg/kg every 8 hours; dexamethasone, 4 mg twice daily; and HAART with a 3-in-1 formulation (efavirenz, 600 mg; emtricitabine, 200 mg; and tenofovir, 300 mg, once daily). She was discharged 7 days later after clinical and radiographic improvement (Figure, B) . Her oral outpatient regimen was fluconazole; azithromycin; trimethoprim-sulfamethoxazole; and prednisone, 40 mg/d, weaning by 10 mg weekly.
The patient was readmitted on 20 October 2008 with left hemiparesis for 48 hours and headaches for 2 weeks. She was still receiving prednisone, 10 mg/d. The mass in the left basal nuclei persisted, with more vasogenic edema and new, bilateral but smaller contrastenhancing lesions (Figure, C) . Her CD4 cell count was 137 ϫ 10 9 cells/L. After a literature search and review of her magnetic resonance imaging studies, we decided to perform a biopsy with primary CNS lymphoma in the differential diagnosis. On immunohistochemical analysis, we saw abundant tachyzoites ( Figure, D) , confirming that this woman had IRIS. We continued the same treatment, tapering the steroid dose over 6 weeks instead of 1 month. She only had slower alternating movements in the left hand when she came for an office visit in December 2008.
The immune inflammatory reconstitution syndrome, a wellrecognized complication of HAART, is the transient exacerbation of an opportunistic infection as the CD4 cell count increases and HIV-1 RNA copies decrease with antiretroviral treatment (1) . About 10% to 30% of patients beginning HAART develop IRIS; the patients at highest risk are HAART-naive and young and start treatment during a recent diagnosis of an opportunistic infection (2) . In the CNS, Mycobacterium tuberculosis and Cryptococcus neoformans, but not T. gondii, have been clearly and consistently linked to IRIS (2, 3). We learned from this experience that patients with AIDS who present with CNS toxoplasmosis and begin HAART may also be at risk for IRIS; this is important because the main differential diagnosis is primary CNS lymphoma, a condition that is sometimes difficult to differentiate from CNS toxoplasmosis. If IRIS is suspected in a patient with HIV-1 infection and CNS toxoplasmosis, close observation for 7 to 15 days, a higher steroid dose to control IRIS (4), uninterrupted HAART, and ongoing treatment for toxoplasmosis can resolve the problem without biopsy. 
